Research activities focus on sarcomas and encompass diverse areas, ranging from biochemical studies and translational research aimed at developing new therapies for treating sarcomas to biochemical predictors of disease.

• We are focusing on chemotherapeutic drug resistance and mechanisms of antiangiogenesis agents. The sensitivity of sarcoma cells to the novel marine chemotherapeutic, Ecteinascidin-743 (ET- 743), has led us and others to consider this compound as an important component of future treatment options for sarcomas such as chondrosarcoma.
• We have also been studying the properties of a novel, protein designated plasminogen-related protein B (PRP-B), encoded for by plasminogen-related gene B (PRG-B), with the goal of extending our understanding of the antiangiogenic process as it relates to tumor growth as well as gaining insights into biological processes that are insensitive to the action of antiangiogenesis inhibitors.
• A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas

Read more on clinical research in cancers of the soft tissue and connective tissue.